BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dupont-Lucas C, Sternszus R, Ezri J, Leibovitch S, Gervais F, Amre D, Deslandres C. Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's Disease. J Crohns Colitis 2016;10:795-804. [PMID: 26822611 DOI: 10.1093/ecco-jcc/jjw038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Xu Y, Guo Z, Huang L, Gong J, Li Y, Gu L, Shen W, Zhu W. A nomogram for predicting the response to exclusive enteral nutrition in adult patients with isolated colonic Crohn's disease. Therap Adv Gastroenterol. 2019;12:1756284819881301. [PMID: 31656533 DOI: 10.1177/1756284819881301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 van Rheenen H, van Rheenen PF. Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies. Pediatr Gastroenterol Hepatol Nutr 2020;23:121-31. [PMID: 32206624 DOI: 10.5223/pghn.2020.23.2.121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
4 Ashton JJ, Mossotto E, Ennis S, Beattie RM. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr 2019;8:56-69. [PMID: 30881899 DOI: 10.21037/tp.2018.12.03] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
5 Yokoyama K, Yamazaki K, Katafuchi M, Ferchichi S. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab. Adv Ther 2016;33:1947-63. [PMID: 27664107 DOI: 10.1007/s12325-016-0406-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Giachero F, Jenke A, Zilbauer M. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. Expert Rev Clin Immunol 2021;17:871-81. [PMID: 34142929 DOI: 10.1080/1744666X.2021.1945442] [Reference Citation Analysis]
7 Agrawal G, Clancy A, Sharma R, Huynh R, Ramrakha S, Borody T. Targeted Combination Antibiotic Therapy Induces Remission in Treatment-Naïve Crohn's Disease: A Case Series. Microorganisms 2020;8:E371. [PMID: 32155771 DOI: 10.3390/microorganisms8030371] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
8 Tarnok A, Kiss Z, Kadenczki O, Veres G. Characteristics of biological therapy in pediatric patients with Crohn's disease. Expert Opin Biol Ther 2019;19:181-96. [PMID: 30601083 DOI: 10.1080/14712598.2019.1564034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Subramanian S, Ekbom A, Rhodes JM. Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD? Gut. 2017;66:362-381. [PMID: 27802156 DOI: 10.1136/gutjnl-2016-312673] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]